SCHEMBL791742

SCHEMBL791742

C[C@@H](c1ccccc1)[C@H](O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
LMNA P02545 3/20 0.62
ADRA2C P18825 2/20 0.62
ADRA2A P08913 1/20 0.62
HIF1A Q16665 1/20 0.62
ALDH1A1 P00352 3/20 0.60
CHRM2 P08172 1/20 0.58
ADRA1A P35348 1/20 0.58
RGS12 O14924 1/20 0.58
GLA P06280 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
PKM P14618 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
ALOX12 P18054 1/20 0.58
NFKB1 P19838 1/20 0.58
HTR2A P28223 1/20 0.58
CYP2C19 P33261 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16174384 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL2483568 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL8230082 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL12581063 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL12435784 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL16172571 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL23626333 0.81 LMNA (0.52) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL8889599 0.81 LMNA (0.52) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL517001 0.81 KDM4E (0.65) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL6689612 0.81 KDM4E (0.65) KDM4ELMNAADRA2CADRA2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541593-B2 Process for making substituted 2-amino-thiazolones AMGEN INC. (US) 2013-09-24 US disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES AMGEN INC. (US) 2010-11-04 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 KDM4E 780/4885LMNA 201/4885ADRA2C 27/4885
US-20100280255-A1 PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES HSD11B1, HSD11B2, HSD17B1 KDM4E 2034/4885LMNA 1477/4885ADRA2C 1342/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 KDM4E 2725/4885LMNA 4323/4885ADRA2C 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.